Show simple item record

dc.contributor.authorOlmedo, Llum
dc.contributor.authorAzagra, Rafael
dc.contributor.authorAguyé, Amada
dc.contributor.authorPascual, Marta
dc.contributor.authorCalvet, Xavier
dc.contributor.authorGené Tous, Emilio Miguel
dc.date.accessioned2021-09-21T11:40:19Z
dc.date.available2021-09-21T11:40:19Z
dc.date.issued2020
dc.identifier.citationOlmedo, Llum; Azagra, Rafael; Aguyé, Amada [et al.]. High effectiveness of a 14-day concomitant therapy for helicobacter pylori treatment in primary care. An observational multicenter study. Journal of Clinical Medicine, 2020, 9(8), 2410. Disponible en: <https://www.mdpi.com/2077-0383/9/8/2410>. Fecha de acceso: 21 sep. 2021. DOI: 10.3390/jcm9082410ca
dc.identifier.issn2077-0383ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/2808
dc.description.abstractBackground: The current cure rates with triple therapy combining a proton-pump inhibitor, amoxicillin and clarithromycin are unacceptably low. Aims: To evaluate the efficacy of a 14-day concomitant therapy as an empirical first-line treatment for curing Helicobacter pylori (Hp) infection in primary care. Methods: Patients from six primary care centers in Catalonia -Spain- were included consecutively. Hp status pre and post treatment was assessed according to local clinical practice protocol. A 14-day concomitant therapy (amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg plus omeprazole 20 mg, all drugs administered twice daily) was prescribed. Adherence to therapy and adverse events were assessed by personal interview. Results: 112 patients were enrolled. Mean age was 46.7 ± 16.1 years. Main indication for treatment was non-investigated dyspepsia (83%). Hp eradication was achieved in 100 of the 112 patients. Eradication rates were 89.3% (95% CI: 81.7–94.1) by intention-to-treat (ITT) analysis and 91.7% (95% CI; 84.6–95.9) per protocol (PP). No major side effects were reported; 104 (92.8%) patients complete the treatment. Forty-seven patients (42%) complained of mild side effects (metallic taste, nausea). Low adherence to treatment (p = 0.004) and significant adverse events (p = 0.004) were the variables associated with treatment failure. Conclusions: In primary care, a 14-day concomitant therapy is highly effective and well tolerated.en
dc.format.extent8ca
dc.language.isoengca
dc.publisherMDPIca
dc.relation.ispartofJournal of Clinical Medicineca
dc.relation.ispartofseries9;8
dc.rightsThis is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherHelicobacterca
dc.subject.otherEradicacióca
dc.subject.otherTractamentca
dc.subject.otherConcomitantca
dc.subject.otherAtenció primàriaca
dc.subject.otherMulticèntricca
dc.subject.otherHelicobacteres
dc.subject.otherErradicaciónes
dc.subject.otherTratamientoes
dc.subject.otherConcomitantees
dc.subject.otherAtención primariaes
dc.subject.otherMulticéntricoes
dc.subject.otherHelicobacteren
dc.subject.otherEradicationen
dc.subject.otherTreatmenten
dc.subject.otherConcomitanten
dc.subject.otherPrimary careen
dc.subject.otherMulticenteren
dc.titleHigh effectiveness of a 14-day concomitant therapy for helicobacter pylori treatment in primary care. An observational multicenter studyen
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616.3ca
dc.identifier.doihttps://dx.doi.org/10.3390/jcm9082410ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint